Integration of surgery and systemic therapy in the management of metastatic renal cancer.
Integration of surgery and systemic therapies represents the best management option for most patients with metastatic renal cell carcinoma. Cytoreductive nephrectomy, metastasectomy, and consolidative surgery can all play a vital role in this challenging patient population. Relevant issues in this era relate to the timing of surgery, the role of cytoreduction as systemic therapies become more effective, management of the residual mass, and surgical safety after targeted therapy.
Thomas
Anil A
AA
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Desk A100, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Rini
Brian I
BI
Campbell
Steven C
SC
D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D009392:Nephrectomy / Q000379:methods